Anti-interleukin-8 monoclonal antibody

Drug Profile

Anti-interleukin-8 monoclonal antibody

Alternative Names: ABX-IL8; Anti-IL-8 antibody

Latest Information Update: 10 Sep 2008

Price : $50

At a glance

  • Originator XenoTech LLC
  • Developer Abgenix; XenoTech
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Inflammation; Inflammatory bowel diseases; Malignant melanoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 02 Dec 2004 A study has been added to the adverse events and Respiratory Tract Disorders therapeutic trials sections
  • 22 Mar 2004 ABX-IL8 is available for licensing in the indication of chronic obstructive pulmonary disease (http://www.abgenix.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top